ThoraGenix

ThoraGenix Innovations Inc. is a Tampa-based medical device manufacturer specializing in innovative surgical solutions for cardiothoracic and thoracic procedures. The company develops biocompatible bone graft substitutes and hemostatic control products designed to enhance sternal healing and rib fracture repair. Their flagship product, ThoraGraft, is a patented biocompatible bone graft substitute (DBM and synthetic) that promotes optimal healing and union of the sternum while providing structural support and encouraging natural bone growth. ThoraGraft addresses the clinical need for improved outcomes in the 2.7 million chest surgeries performed annually that require sternal access. The company also manufactures ThoraPutty IRM, an FDA-approved osteostimulative and bioactive synthetic material for bone voids and fractures, offering anti-bacterial effects, enhanced healing properties, and mechanical hemostasis. With over 700 cases performed in the US and a 95% satisfaction rate, ThoraGenix combines clinical expertise (120 combined years among the executive team) with patentable technology to transform cardiothoracic care outcomes.